<DOC>
	<DOCNO>NCT00687713</DOCNO>
	<brief_summary>This study ass efficacy bupropion reduce methamphetamine use subject methamphetamine dependence report use methamphetamine 29 less day 30 day prior start sign consent .</brief_summary>
	<brief_title>Phase 2 , Double-Blind , Placebo-Controlled Trial Bupropion Methamphetamine Dependence</brief_title>
	<detailed_description>The primary objective study assess efficacy bupropion reduce methamphetamine use subject methamphetamine dependence report use methamphetamine 29 less day 30 day prior sign consent . Secondary objective include limited : assess success failure achieve abstinence ( confirm least two methamphetaminenegative urine methamphetamine-positive urine ) week last two week ( Weeks 11 12 ) subject use methamphetamine 18 less day 30 day prior sign consent , assess safety bupropion study population , assess measure efficacy bupropion reduce methamphetamine use craving , psychological assessment methamphetamine dependence . It hypothesize bupropion , compare placebo , would associate increase proportion subject achieve abstinence ( confirm least two methamphetamine-negative urine methamphetaminepositive urine ) week last two week ( Weeks 11 12 ) non-daily user .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Must DSMIV diagnosis methamphetamine dependence determine MINI Must least 1 amphetamine methamphetamine positive urine specimen start screen randomization provide information verify recent use positive urine sample ca n't obtain Must report use methamphetamine 29 day less 30 day period prior sign consent use timeline followback method Must willing able comply study procedure Must able verbalize understand consent form provide write informed consent Must seek treatment methamphetamine dependence Please contact study site information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>